



## Prior Authorization Approval Criteria

### Valcyte (valganciclovir)

<b>Generic name:</b>	valganciclovir
<b>Brand name:</b>	Valcyte
<b>Medication class:</b>	Antiviral
<b>FDA-approved uses:</b>	-treatment of cytomegalovirus (CMV) retinitis in patients with acquired immunodeficiency syndrome (AIDS). -prevention of CMV disease in kidney, heart, or kidney-pancreas transplant patients at high risk (Donor CMV seropositive/Recipient CMV seronegative [D+/R-]).
<b>Available dosage forms:</b>	oral solution 50 mg/ml Tablet 450mg
<b>Usual dose:</b>	CMV treatment in AIDS patients- 900mg twice daily for 14-21 day followed by 900mg daily CMV prophylaxis in transplants- 900 milligrams orally once daily. Therapy should begin within 10 days of transplantation and continue through day 100 post transplantation in heart or kidney-pancreas transplant patients, and through day 200 post transplantation in kidney transplant patients.
<b>Criteria for use</b> <i>(bullet points below are all inclusive unless otherwise noted):</i>	<ul style="list-style-type: none"><li>• The indicated diagnosis (including any applicable labs and /or tests) and medication usage must be supported by documentation from the patient's medical records.</li><li>• Prevention of CMV disease in kidney, heart, or kidney-pancreas transplant patients at high risk (Donor CMV seropositive/Recipient CMV seronegative [D+/R-]).</li><li>• Treatment of cytomegalovirus (CMV) retinitis in patients with acquired immunodeficiency syndrome (AIDS).</li><li>• If used for medicare covered transplants, it will be covered under part B</li></ul>

FCHP Pharmacy and Therapeutics Committee approval: \_\_\_\_\_

Date: \_\_\_\_\_

Adopted: 06/08/11